FindTrial
Sign In

Utility of continuous glucose monitoring (CGMS) in children with type I diabetes on intensive treatment regimens

Utility of continuous glucose monitoring (CGMS) in children with type I diabetes on intensive treatment regimens

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN28387915
Enrollment
35
Registered
2005-02-09
Start date
2004-05-01
Completion date
Unknown
Last updated
2020-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Nutritional, Metabolic, Endocrine Diabetes

Interventions

Two arms: 1. Intervention arm has CGMS monitoring for 3 days every 3 weeks over a 3 month period (4 cycles) 2. Control arm that continues traditional intermittent blood

Sponsors

Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Children and adolescents aged 18 years or less with type one diabetes on either an insulin pump or an intensive insulin plan that includes insulin glargine (Lantus) for at least 3 months.

Exclusion criteria

Exclusion criteria: 1. Known poor compliance 2. HbA1c greater than 10%

Design outcomes

Primary

MeasureTime frame
Diabetes control, measured using HbA1c and fructosamine measured at baseline and 6 and 12 weeks.—

Secondary

MeasureTime frame
1. HbA1c, measured using ion-exchange high-pressure liquid chromatography (Bio-Rad Laboratories) 2. Fructosamine, measured using Cobras Integras system—

Countries

Australia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026